Turn Therapeutics (TTRX) Non-Current Deffered Revenue (2024 - 2026)

Turn Therapeutics has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (changed N/A YoY), and the FY2025 full-year result was $1.4 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $1.4 million, roughly flat from $1.4 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $1.4 million in Q4 2024, with the low at $1.4 million in Q4 2024.
• Average Non-Current Deffered Revenue over 3 years is $1.4 million, with a median of $1.4 million recorded in 2024.
• Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2025, while the deepest fall reached 0.0% in 2025.
• Tracing TTRX's Non-Current Deffered Revenue over 3 years: stood at $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025, then changed by 0.0% to $1.4 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.

Peer Comparison